{"bundle_type":"pith_open_graph_bundle","bundle_version":"1.0","pith_number":"pith:2016:AULGSYAXTOX27CJ5IYINZNK6XF","short_pith_number":"pith:AULGSYAX","canonical_record":{"source":{"id":"1604.04913","kind":"arxiv","version":1},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.TO","submitted_at":"2016-04-17T19:16:17Z","cross_cats_sorted":["math.OC","q-bio.PE"],"title_canon_sha256":"03de667e98ed74350c89864a03b62ddef0f69bf3d360d24a1a3d45d066732938","abstract_canon_sha256":"f4f49539f85e73591f7d513bd565fbcca34df4cc68a6cb121e9f85ee018d1cdb"},"schema_version":"1.0"},"canonical_sha256":"05166960179bafaf893d4610dcb55eb94367d6f50003da7716e62d71303724a3","source":{"kind":"arxiv","id":"1604.04913","version":1},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1604.04913","created_at":"2026-05-18T00:51:17Z"},{"alias_kind":"arxiv_version","alias_value":"1604.04913v1","created_at":"2026-05-18T00:51:17Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1604.04913","created_at":"2026-05-18T00:51:17Z"},{"alias_kind":"pith_short_12","alias_value":"AULGSYAXTOX2","created_at":"2026-05-18T12:30:07Z"},{"alias_kind":"pith_short_16","alias_value":"AULGSYAXTOX27CJ5","created_at":"2026-05-18T12:30:07Z"},{"alias_kind":"pith_short_8","alias_value":"AULGSYAX","created_at":"2026-05-18T12:30:07Z"}],"events":[{"event_type":"record_created","subject_pith_number":"pith:2016:AULGSYAXTOX27CJ5IYINZNK6XF","target":"record","payload":{"canonical_record":{"source":{"id":"1604.04913","kind":"arxiv","version":1},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.TO","submitted_at":"2016-04-17T19:16:17Z","cross_cats_sorted":["math.OC","q-bio.PE"],"title_canon_sha256":"03de667e98ed74350c89864a03b62ddef0f69bf3d360d24a1a3d45d066732938","abstract_canon_sha256":"f4f49539f85e73591f7d513bd565fbcca34df4cc68a6cb121e9f85ee018d1cdb"},"schema_version":"1.0"},"canonical_sha256":"05166960179bafaf893d4610dcb55eb94367d6f50003da7716e62d71303724a3","receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-05-18T00:51:17.660907Z","signature_b64":"vt0s26LtnAbejCi3uAUQvmhiD3nyp9WWQcuHJ0qcSyGfNPepvR85CrId1wH65mh6gEq3yQFHoNBjBAIPLH19Aw==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"05166960179bafaf893d4610dcb55eb94367d6f50003da7716e62d71303724a3","last_reissued_at":"2026-05-18T00:51:17.660236Z","signature_status":"signed_v1","first_computed_at":"2026-05-18T00:51:17.660236Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"source_kind":"arxiv","source_id":"1604.04913","source_version":1,"attestation_state":"computed"},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-18T00:51:17Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"bQ3fz6UqFhtpN7ni/d/yJagFZjaMCFU9KxsNXGqQP/GEJ0aKMJfVIYN5MvQdv6YYexqiApN7CP+cKlcjFBizDA==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-05-30T08:58:17.302761Z"},"content_sha256":"6ff07a13b719b305d736bd0f8fca4be8d6b719ca7a200dda1b4fec0cf0e52336","schema_version":"1.0","event_id":"sha256:6ff07a13b719b305d736bd0f8fca4be8d6b719ca7a200dda1b4fec0cf0e52336"},{"event_type":"graph_snapshot","subject_pith_number":"pith:2016:AULGSYAXTOX27CJ5IYINZNK6XF","target":"graph","payload":{"graph_snapshot":{"paper":{"title":"Optimized Treatment Schedules for Chronic Myeloid Leukemia","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","headline":"","cross_cats":["math.OC","q-bio.PE"],"primary_cat":"q-bio.TO","authors_text":"David Dingli, Jasmine Foo, Junfeng Zhu, Kevin Leder, Qie He","submitted_at":"2016-04-17T19:16:17Z","abstract_excerpt":"Over the past decade, several targeted therapies (e.g. imatinib, dasatinib, nilotinib) have been developed to treat Chronic Myeloid Leukemia (CML). Despite an initial response to therapy, drug resistance remains a problem for some CML patients. Recent studies have shown that resistance mutations that preexist treatment can be detected in a substan- tial number of patients, and that this may be associated with eventual treatment failure. One proposed method to extend treatment efficacy is to use a combination of multiple targeted therapies. However, the design of such combination therapies (tim"},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1604.04913","kind":"arxiv","version":1},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"verdict_id":null},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-18T00:51:17Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"tlxe0j+Sjjrc8JQYqysz2tAes3TJPRK0cpUyyDI5bSoDh/o/Y3VLNpK6AbIfKOUxW/xvGIxKV7shYgiv3EsnAw==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-05-30T08:58:17.303153Z"},"content_sha256":"09878872706477f5b36c869b0f891760dcddbf389da3987e8a8f46882b159c93","schema_version":"1.0","event_id":"sha256:09878872706477f5b36c869b0f891760dcddbf389da3987e8a8f46882b159c93"}],"timestamp_proofs":[],"mirror_hints":[{"mirror_type":"https","name":"Pith Resolver","base_url":"https://pith.science","bundle_url":"https://pith.science/pith/AULGSYAXTOX27CJ5IYINZNK6XF/bundle.json","state_url":"https://pith.science/pith/AULGSYAXTOX27CJ5IYINZNK6XF/state.json","well_known_bundle_url":"https://pith.science/.well-known/pith/AULGSYAXTOX27CJ5IYINZNK6XF/bundle.json","status":"primary"}],"public_keys":[{"key_id":"pith-v1-2026-05","algorithm":"ed25519","format":"raw","public_key_b64":"stVStoiQhXFxp4s2pdzPNoqVNBMojDU/fJ2db5S3CbM=","public_key_hex":"b2d552b68890857171a78b36a5dccf368a953413288c353f7c9d9d6f94b709b3","fingerprint_sha256_b32_first128bits":"RVFV5Z2OI2J3ZUO7ERDEBCYNKS","fingerprint_sha256_hex":"8d4b5ee74e4693bcd1df2446408b0d54","rotates_at":null,"url":"https://pith.science/pith-signing-key.json","notes":"Pith uses this Ed25519 key to sign canonical record SHA-256 digests. Verify with: ed25519_verify(public_key, message=canonical_sha256_bytes, signature=base64decode(signature_b64))."}],"merge_version":"pith-open-graph-merge-v1","built_at":"2026-05-30T08:58:17Z","links":{"resolver":"https://pith.science/pith/AULGSYAXTOX27CJ5IYINZNK6XF","bundle":"https://pith.science/pith/AULGSYAXTOX27CJ5IYINZNK6XF/bundle.json","state":"https://pith.science/pith/AULGSYAXTOX27CJ5IYINZNK6XF/state.json","well_known_bundle":"https://pith.science/.well-known/pith/AULGSYAXTOX27CJ5IYINZNK6XF/bundle.json"},"state":{"state_type":"pith_open_graph_state","state_version":"1.0","pith_number":"pith:2016:AULGSYAXTOX27CJ5IYINZNK6XF","merge_version":"pith-open-graph-merge-v1","event_count":2,"valid_event_count":2,"invalid_event_count":0,"equivocation_count":0,"current":{"canonical_record":{"metadata":{"abstract_canon_sha256":"f4f49539f85e73591f7d513bd565fbcca34df4cc68a6cb121e9f85ee018d1cdb","cross_cats_sorted":["math.OC","q-bio.PE"],"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.TO","submitted_at":"2016-04-17T19:16:17Z","title_canon_sha256":"03de667e98ed74350c89864a03b62ddef0f69bf3d360d24a1a3d45d066732938"},"schema_version":"1.0","source":{"id":"1604.04913","kind":"arxiv","version":1}},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1604.04913","created_at":"2026-05-18T00:51:17Z"},{"alias_kind":"arxiv_version","alias_value":"1604.04913v1","created_at":"2026-05-18T00:51:17Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1604.04913","created_at":"2026-05-18T00:51:17Z"},{"alias_kind":"pith_short_12","alias_value":"AULGSYAXTOX2","created_at":"2026-05-18T12:30:07Z"},{"alias_kind":"pith_short_16","alias_value":"AULGSYAXTOX27CJ5","created_at":"2026-05-18T12:30:07Z"},{"alias_kind":"pith_short_8","alias_value":"AULGSYAX","created_at":"2026-05-18T12:30:07Z"}],"graph_snapshots":[{"event_id":"sha256:09878872706477f5b36c869b0f891760dcddbf389da3987e8a8f46882b159c93","target":"graph","created_at":"2026-05-18T00:51:17Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"graph_snapshot":{"author_claims":{"count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","strong_count":0},"builder_version":"pith-number-builder-2026-05-17-v1","claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"paper":{"abstract_excerpt":"Over the past decade, several targeted therapies (e.g. imatinib, dasatinib, nilotinib) have been developed to treat Chronic Myeloid Leukemia (CML). Despite an initial response to therapy, drug resistance remains a problem for some CML patients. Recent studies have shown that resistance mutations that preexist treatment can be detected in a substan- tial number of patients, and that this may be associated with eventual treatment failure. One proposed method to extend treatment efficacy is to use a combination of multiple targeted therapies. However, the design of such combination therapies (tim","authors_text":"David Dingli, Jasmine Foo, Junfeng Zhu, Kevin Leder, Qie He","cross_cats":["math.OC","q-bio.PE"],"headline":"","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.TO","submitted_at":"2016-04-17T19:16:17Z","title":"Optimized Treatment Schedules for Chronic Myeloid Leukemia"},"references":{"count":0,"internal_anchors":0,"resolved_work":0,"sample":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1604.04913","kind":"arxiv","version":1},"verdict":{"created_at":null,"id":null,"model_set":{},"one_line_summary":"","pipeline_version":null,"pith_extraction_headline":"","strongest_claim":"","weakest_assumption":""}},"verdict_id":null}}],"author_attestations":[],"timestamp_anchors":[],"storage_attestations":[],"citation_signatures":[],"replication_records":[],"corrections":[],"mirror_hints":[],"record_created":{"event_id":"sha256:6ff07a13b719b305d736bd0f8fca4be8d6b719ca7a200dda1b4fec0cf0e52336","target":"record","created_at":"2026-05-18T00:51:17Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"attestation_state":"computed","canonical_record":{"metadata":{"abstract_canon_sha256":"f4f49539f85e73591f7d513bd565fbcca34df4cc68a6cb121e9f85ee018d1cdb","cross_cats_sorted":["math.OC","q-bio.PE"],"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.TO","submitted_at":"2016-04-17T19:16:17Z","title_canon_sha256":"03de667e98ed74350c89864a03b62ddef0f69bf3d360d24a1a3d45d066732938"},"schema_version":"1.0","source":{"id":"1604.04913","kind":"arxiv","version":1}},"canonical_sha256":"05166960179bafaf893d4610dcb55eb94367d6f50003da7716e62d71303724a3","receipt":{"algorithm":"ed25519","builder_version":"pith-number-builder-2026-05-17-v1","canonical_sha256":"05166960179bafaf893d4610dcb55eb94367d6f50003da7716e62d71303724a3","first_computed_at":"2026-05-18T00:51:17.660236Z","key_id":"pith-v1-2026-05","kind":"pith_receipt","last_reissued_at":"2026-05-18T00:51:17.660236Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","receipt_version":"0.3","signature_b64":"vt0s26LtnAbejCi3uAUQvmhiD3nyp9WWQcuHJ0qcSyGfNPepvR85CrId1wH65mh6gEq3yQFHoNBjBAIPLH19Aw==","signature_status":"signed_v1","signed_at":"2026-05-18T00:51:17.660907Z","signed_message":"canonical_sha256_bytes"},"source_id":"1604.04913","source_kind":"arxiv","source_version":1}}},"equivocations":[],"invalid_events":[],"applied_event_ids":["sha256:6ff07a13b719b305d736bd0f8fca4be8d6b719ca7a200dda1b4fec0cf0e52336","sha256:09878872706477f5b36c869b0f891760dcddbf389da3987e8a8f46882b159c93"],"state_sha256":"3aab9a3a632b0b23130a789d5c98358da4597acd2852eee9c7a0366ea4066de1"},"bundle_signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"fwu72YTH27vQI9zBapn40nQlqgjgE/gx005x9XVmK+1gGb3nz9KcotKFoANrIh6xNErrxkjTPeGx2z1F5mnOCg==","signed_message":"bundle_sha256_bytes","signed_at":"2026-05-30T08:58:17.305489Z","bundle_sha256":"a2918a0f4c97c9a9f35962b3113ac8a008dd1d3b28f31dc1766b0ef3f9ad9a48"}}